Venture Capital for Deep-Tech and HealthTech Technologies
Investment in deep-tech, healthtech
and life science is an investment for the future
Our Mission
Promote deep-tech, healthtech and technological innovation by investing in breakthrough technologies and providing support from industry leaders, while changing the investment fund’s traditional paradigm, allowing its investors to benefit from better liquidity and transparency.
Our Investment Focus
Digital Health
Healthcare AI
Medical Devices & Robotics
Advanced Innovative Technologies
Deep-Tech
Cyber Security
Advantages
Why Peaks-Giza Ventures
A vehicle for investments in deep-tech and healthtech technologies, providing projects a funding platform.
Investors
Investors have the option to benefit from better liquidity.
Desicion making
Peaks-Giza investors will be informed regarding the investment decision-making.
No limits
For Peaks-Giza no time limitation for investments and Exits.
Worldwide
Almost no geographical limitations.
Participation in Peaks-Giza incubation program provides early-stage startups with support from best experts in the industry.
Peaks-Giza Ventures offers a full support: starting with a project “package” and up to the stage of entering the market.
Our Team
Founders and Management Team
Managing partner, Chairman & CEO
Moshe Kamar
Managing partner, Chairman & CEO
Managing partner, President
Mira Peled
Managing partner, President
Managing partner, Head of Tech and AI
Sharon (Gigi) Greenberg
Managing partner, Head of Tech and AI
Business and Investments
Zeev Holtzman
Business and Investments
CEO and Managing partner at Compass Ventures Group and former President of the Advertising & Media division at Amdocs and senior manager in many leading multinational companies, he is an experienced international executive manager and investor with an impressive track record in technology companies, specializing in fund management and leading global investment projects in technology and innovation. His expertise includes sourcing cutting-edge technology products and solution in a range of sectors, and bringing them to market, with a focus on international markets.
Moshe Kamar
CEO of Peaks Ventures & former Co-Founder & CEO of AIT and BioMimic Pharma; both have been acquired by US companies. She has worked for leading Israeli biotech companies and has been involved in establishing a number of start-up companies. She has served as an advisor for investors and accelerators in the life science field in Israel.
Mira Peled Kamar
CEO of EverFlow and a Blockchain serial entrepreneur with extensive experience in the start-up sphere. Over 15 years of executive role at tech companies, with a broad network of contacts in various vertical markets globally. An early stage investor in various ventures in the fintech market.
Sharon Greenberg
Past Performance
Over
$
0
M
Invested
Over
0
Investments
Over
0
exits
with total value about $8B
High IRR
Over
$
0
M
Invested
Over
0
Investments
Over
0
exits
with total value overt $8B
High IRR
Strategic Partners
Fund Advantages
» Strong, experienced and hands-on management team
» Hybrid model that enhanced liquidity for accredited investors
» Access to disruptive healthcare technologies creates a unique deal-flow
» Wide network with academic institutions, industry leaders, experts
» Collaborations with Israeli leading hospitals
» Existing attractive deal flow for investment
Companies Seeking Capital
At Peaks-Giza Ventures, our experienced team is dedicated to discovering and researching a multitude of cutting-edge technological opportunities.
Join us to access these opportunities
An innovative immunotherapy company
Cancer is a major cause of death worldwide. There is a huge unmet need for novel cancer therapies, but the greatest challenge is the lack of good targets.
Cancer cells shield themselves with sugar-coating to evade the immune system. Cell surface glycans have different abnormal structures that are not found in healthy cells. So the cancer cell sugar-coat is actually different, generating carbohydrate-neoantigens (cAg) that are excellent targets for cancer therapy.
Glyconia developed an innovative technology targeting cAgs on cancer cells with engineered CAR-T, turning them into cancer-killing machines for optimal efficacy, particularly in solid tumors.
Body mole mapping and tracking system
Marpé Technologies is a science based company developing innovative scanners for early detection of skin cancer.
Prototype scanners are operating at the Tel Aviv Sourasky Medical Center and the Bnei Zion Medical Center in Haifa, both leading hospitals in Israel, indicating the superior features of Marpe’s technology.
Detecting early vital
warning signs
ATLASense Platform is the only personalized, continuous, and comprehensive health surveillance system to assist in the prevention of deterioration by detecting unique early warning signs both in-hospital and at home.
Portable home dialysis - only 20 minutes each session
Patients can dialyze from home, work, or while on vacation while going about their regular lives thanks to iRen portable iDA devices and still being remotely monitored to personalize the therapy. The dialysis provided by iRen technology is safe, simple to use, and affordable. It takes 20 minutes, 3 sessions a day.
An innovative immunotherapy company
Cancer is a major cause of death worldwide. There is a huge unmet need for novel cancer therapies, but the greatest challenge is the lack of good targets.
Cancer cells shield themselves with sugar-coating to evade the immune system. Cell surface glycans have different abnormal structures that are not found in healthy cells. So the cancer cell sugar-coat is actually different, generating carbohydrate-neoantigens (cAg) that are excellent targets for cancer therapy.
Glyconia developed an innovative technology targeting cAgs on cancer cells with engineered CAR-T, turning them into cancer-killing machines for optimal efficacy, particularly in solid tumors.
Body mole mapping and tracking system
Marpé Technologies is a science based company developing innovative scanners for early detection of skin cancer.
Prototype scanners are operating at the Tel Aviv Sourasky Medical Center and the Bnei Zion Medical Center in Haifa, both leading hospitals in Israel, indicating the superior features of Marpe’s technology.
Detecting early vital
warning signs
ATLASense Platform is the only personalized, continuous, and comprehensive health surveillance system to assist in the prevention of deterioration by detecting unique early warning signs both in-hospital and at home.
Transforming Breast Cancer Care With AI Agents
MEDow.AI is Transforming Breast Cancer Care With AI Agents. With our Patient-Centered Conversational AI Platform, Clinics gain a centralized dashboard to monitor patient health, flag urgent needs, and deploy proactive workflows and their patients receive a 24/7 personalized AI companion.
Nevia
Nevia bio is a developing a machine learning based platform of early detection in women’s health space, using an untapped biofluid- vaginal secretions. The Nevia platform is designed to decode data from biofluids, and to gain insights about physiological conditions, presenting promising clinical results in its first indication: ovarian cancer.
More investment opportunities
Want to see more exclusive, carefully selected investment opportunities?
Register now to get full access to our exclusive list here